🔎 Trials Near Me

Akèy › Kasinom selil skuam › Massachusetts

Etid klinik pou Kasinom selil skuam nan Massachusetts

8 etid pou Kasinom selil skuam ap chèche patisipan nan sit nan Massachusetts.

Vil nan Massachusetts

Tèks ofisyèl etid la (Anglè)

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  • Boston Medical Center, Boston
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04892173

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Tufts Medical Center, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06561685

Toripalimab With Chemotherapy for Sinus Cancer

  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06940180

PDT For Induction Therapy For Head And Neck Cancer

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07214987

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06064877

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT04370587

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

  • Dana Farber/Partners Cancer Care Inc, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.